Why AI in Health? A societal emergency
Medical innovation saves lives, but the delays between discovery and patient access remain dramatically long. Meanwhile, our health systems are facing an unsolvable equation: a growing demand for care, an alarming scarcity of practitioners, and constrained budgets. This tension is not conjunctural – it is structural. We will inevitably have to do more, better and faster, with fewer resources and less time.
Artificial intelligence is not a technological option among others: it is a societal imperative. Every hour saved in diagnosis, every optimized process, every MedTech innovation accelerated directly translates into lives saved and sufferings avoided.
It is this conviction that guides my engagement with QARAlink, a unique Swiss platform in Europe simplifying regulatory compliance to accelerate the market launch of innovative medical devices, and ANATOPIX, a French deeptech developing apre-screening for digestive inflammatory diseases.
Two complementary approaches to the same fight: freeing up medical time where it counts most - with patients - and allowing innovations that save lives to reach those who need them, faster.
Because in the field of health, time is never neutral. It heals or it kills.
Reinventing the MedTech Regulatory Compliance
Bringing an innovative medical device to market is a regulatory obstacle course. Between MDR/IVDR, the EU AI Act, ISO standards, and complex technical dossiers, MedTech manufacturers waste precious time in labyrinthine administrative processes – to the detriment of innovation and patient access.
QARAlink is transforming this reality. This artificial intelligence platform, unique in Europe, radically simplifies your compliance journey. Designed by regulatory affairs experts, it guides you step by step through your submissions, clarifies regulatory ambiguities, and keeps you compliant with legislative changes in real time.
What we offer you : clarity in complexity, control of your process with customizable tools, maximum security of your sensitive data, intuitive accessibility, and human expertise available when you need it.
The result ? You accelerate your time-to-market , reduce your compliance costs and free up your teams to develop life-changing medical technologies.
Because every day gained in compliance is one more day where your innovation can heal.
Pre-Seed Funding Round USD 936K August 2025
Accelerating the diagnosis of inflammatory bowel diseases
In pathological anatomy , oncology legitimately monopolizes the resources and attention of professionals.
As a result, patients with chronic inflammatory bowel diseases (IBD) – Crohn's disease , ulcerative colitis, celiac disease – experience prolonged diagnostic wandering, sometimes lasting several months, with dramatic consequences for their quality of life.
ANATOPIX is developing an AI-powered pre-screening module capable of analyzing pathology slides for inflammatory bowel diseases in record time. This technology allows pathologists to efficiently prioritize cases, save valuable time on analysis, and significantly accelerate the patient diagnostic process.
Selected for the prestigious BioLaunchpad program of the Imagine Institute (directed by Professor Olivier Hermine), ANATOPIX benefits from the expertise of the greatest French specialists in gastroenterology, pathological anatomy and computer science to develop a solution that will transform the care of millions of patients, all in complete safety and based in France.
Because when it comes to diagnosis, every week gained counts.
